JP7675014B2 - Ｂ細胞免疫療法 - Google Patents

Ｂ細胞免疫療法 Download PDF

Info

Publication number
JP7675014B2
JP7675014B2 JP2021543207A JP2021543207A JP7675014B2 JP 7675014 B2 JP7675014 B2 JP 7675014B2 JP 2021543207 A JP2021543207 A JP 2021543207A JP 2021543207 A JP2021543207 A JP 2021543207A JP 7675014 B2 JP7675014 B2 JP 7675014B2
Authority
JP
Japan
Prior art keywords
cells
cell
injury
animals
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021543207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523680A5 (https=
JPWO2020154534A5 (https=
JP2022523680A (ja
Inventor
マーク シー． ポズナンスキー
ルクサンドラ エフ． シルブレスク
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ホーリー クロス ホスピタル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション, ホーリー クロス ホスピタル インコーポレイテッド filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2022523680A publication Critical patent/JP2022523680A/ja
Publication of JP2022523680A5 publication Critical patent/JP2022523680A5/ja
Publication of JPWO2020154534A5 publication Critical patent/JPWO2020154534A5/ja
Priority to JP2025072923A priority Critical patent/JP2025118706A/ja
Application granted granted Critical
Publication of JP7675014B2 publication Critical patent/JP7675014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
JP2021543207A 2019-01-23 2020-01-23 Ｂ細胞免疫療法 Active JP7675014B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072923A JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962795629P 2019-01-23 2019-01-23
US62/795,629 2019-01-23
US201962837765P 2019-04-24 2019-04-24
US62/837,765 2019-04-24
US202062965032P 2020-01-23 2020-01-23
PCT/US2020/014836 WO2020154534A1 (en) 2019-01-23 2020-01-23 B cell immunotherapy
US62/965,032 2020-01-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072923A Division JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Publications (4)

Publication Number Publication Date
JP2022523680A JP2022523680A (ja) 2022-04-26
JP2022523680A5 JP2022523680A5 (https=) 2023-02-01
JPWO2020154534A5 JPWO2020154534A5 (https=) 2023-02-01
JP7675014B2 true JP7675014B2 (ja) 2025-05-12

Family

ID=71735798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543207A Active JP7675014B2 (ja) 2019-01-23 2020-01-23 Ｂ細胞免疫療法
JP2025072923A Pending JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072923A Pending JP2025118706A (ja) 2019-01-23 2025-04-25 Ｂ細胞免疫療法

Country Status (4)

Country Link
US (1) US20220079986A1 (https=)
JP (2) JP7675014B2 (https=)
CA (1) CA3127623A1 (https=)
WO (1) WO2020154534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4236968A4 (en) * 2020-10-30 2024-03-27 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
JP2024543827A (ja) * 2021-11-11 2024-11-26 ザ ジェネラル ホスピタル コーポレイション 筋萎縮性側索硬化症のステージおよび進行を画定するための方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075434A1 (ja) 2004-02-09 2005-08-18 Mitsubishi Pharma Corporation 筋萎縮性側索硬化症（als）又はalsに起因する疾患の新規治療剤
US20100028296A1 (en) 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
JP2015529084A (ja) 2012-09-06 2015-10-05 デューク ユニバーシティ Ｂ細胞の増加及び評価方法並びに疾患治療のための増加ｂ細胞の使用方法
US20160375059A1 (en) 2008-04-25 2016-12-29 Duke University Regulatory b cells and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2576772B1 (en) * 2010-05-26 2018-12-12 Deutsches Rheuma-Forschungszentrum Berlin Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells
US20140079675A1 (en) * 2011-04-04 2014-03-20 HumaCell, Inc. Repair of Neurodegenerative Diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075434A1 (ja) 2004-02-09 2005-08-18 Mitsubishi Pharma Corporation 筋萎縮性側索硬化症（als）又はalsに起因する疾患の新規治療剤
US20100028296A1 (en) 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
US20160375059A1 (en) 2008-04-25 2016-12-29 Duke University Regulatory b cells and their uses
JP2015529084A (ja) 2012-09-06 2015-10-05 デューク ユニバーシティ Ｂ細胞の増加及び評価方法並びに疾患治療のための増加ｂ細胞の使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cellular and Molecular Immunology，2018年01月08日，Vol. 15，pp. 727-730
J Immunol.，2012年，188(7)，3188-3198

Also Published As

Publication number Publication date
CA3127623A1 (en) 2020-07-30
JP2025118706A (ja) 2025-08-13
WO2020154534A1 (en) 2020-07-30
US20220079986A1 (en) 2022-03-17
JP2022523680A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
JP6803339B2 (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP2025118706A (ja) Ｂ細胞免疫療法
EP3134120B1 (en) Compositions and methods for treating cytokine-related disorders
JP2019047813A (ja) 治療用アポトーシス細胞調製物、その製造方法及びその使用
Li et al. Lymph node fibroblastic reticular cells deposit fibrosis-associated collagen following organ transplantation
Wang et al. Chimeric CNS-targeting-peptide engineered exosomes for experimental autoimmune encephalomyelitis therapy
CA2913274C (en) Human monocyte sub-population for treatment of eye diseases and disorders
CN113677354A (zh) B细胞免疫疗法
Peralta Ramos et al. Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of Alzheimer’s disease
JP7498293B2 (ja) ＮＦ－κＢ抑制剤のエキソソーム基盤伝達の使用
US12508285B2 (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
EP3493835B1 (en) Method for ex vivo induction of suppressor lymphocytes using a solution of proteins from helminth parasites
US20180207192A1 (en) Substance and method for modulating proliferation and differentiation of regulatory, stem and other somatic cells
HK40074225A (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250425

R150 Certificate of patent or registration of utility model

Ref document number: 7675014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150